IntelGenx Seeks Creditor Protection to Navigate Financial Crisis

The pharmaceutical film company initiates restructuring under the CCAA to explore strategic alternatives and ensure business continuity.

IntelGenx faces liquidity issues due to delays in regulatory approvals and securing bridge financing.
The Québec Superior Court has granted creditor protection to provide time for strategic review.
Ernst & Young Inc. appointed as Monitor to assist with restructuring efforts.
Trading of IntelGenx shares on the TSX has been halted pending a review of the company's suitability for listing.
The company aims to implement a sale, investment, or recapitalization process for long-term viability.